MIC of delamanid (OPC-67683) against Mycobacterium tuberculosis clinical isolates and a proposed critical concentration

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 6, 2016, Pages 3316-3322

  Stinson, Kelly ^a,f   Kurepina, Natalia ^b   Venter, Amour ^c   Fujiwara, Mamoru ^d   Kawasaki, Masanori ^d   Timm, Juliano ^e   Shashkina, Elena ^b   Kreiswirth, Barry N ^b   Liu, Yongge ^a   Matsumoto, Makoto ^d   Geiter, Lawrence ^a  

^a OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c UNIVERSITY OF STELLENBOSCH   (South Africa)

^d OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^e Microbiocon   (United States)

^f Cultura   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DELAMANID; NITROIMIDAZOLE DERIVATIVE; OPC-67683; OXAZOLE DERIVATIVE; TUBERCULOSTATIC AGENT;

AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG DETERMINATION; EUROPEAN UNION; HUMAN; MAJOR CLINICAL STUDY; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; SOUTH AFRICA; SOUTH AFRICAN; CLINICAL TRIAL; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TUBERCULOSIS, PULMONARY;

ANTITUBERCULAR AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; NITROIMIDAZOLES; OXAZOLES; TUBERCULOSIS, PULMONARY;

EID: 84973659484     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03014-15     Document Type: Article

References (18)

1. World Health Organization. 2015. Global tuberculosis report. Document WHO/HTM/TB/2015.22. World Health Organization, Geneva, Switzerland.
2. Matsumoto M, Hashizume H, Tomishige T, Kawasaki M, Tsubouchi H, Sasaki H, Shimokawa Y, Komatsu M. 2006. OPC-67683, a nitrodihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med 3:e466. http://dx.doi.org/10.1371 /journal.pmed.0030466.
3. Diacon AH, Dawson R, Hanekom M, Narunsky K, Venter A, Hittel N, Geiter LJ, Wells CD, Paccaly AJ, Donald PR. 2011. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. Int J Tuberc Lung Dis 15:949-954. http://dx.doi.org/10 .5588/ijtld.10.0616.
4. Gler MT, Skripconoka V, Sanchez-Garavito E, Xiao H, Cabrera-Rivero JL, Vargas-Vasquez DE, Gao M, Awad M, Park SK, Shim TS, Suh GY, Danilovits M, Ogata H, Kurve A, Chang J, Suzuki K, Tupasi T, Koh WJ, Seaworth B, Geiter LJ, Wells CD. 2012. Delamanid for multidrugresistant pulmonary tuberculosis. N Engl J Med 366:2151-2160. http://dx .doi.org/10.1056/NEJMoa1112433.
5. Skripconoka V, Danilovits M, Pehme L, Tomson T, Skenders G, Kummik T, Cirule A, Leimane V, Kurve A, Levina K, Geiter LJ, Manissero D, Wells CD. 2013. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J 41:1393-1400. http://dx .doi.org/10.1183/09031936.00125812.
6. Wells CD, Gupta R, Hittel N, Geiter LJ. 2015. Long-term mortality assessment of multidrug-resistant tuberculosis patients treated with delamanid. Eur Respir J 45:1498-1501. http://dx.doi.org/10.1183/09031936 .00176314.
7. Gupta R, Geiter LJ, Wells CD, Gao M, Cirule A, Xiao H. 2015. Delamanid for extensively drug-resistant tuberculosis. N Engl J Med 373: 291-292. http://dx.doi.org/10.1056/NEJMc1415332.
8. Clinical and Laboratory Standards Institute. 2008. Development of in vitro susceptibility testing criteria and quality control parameters; approved guideline, 3rd ed. Document M23-A3. CLSI, Wayne, PA.
9. Parsons LM, Brosch R, Cole ST, Somoskovi A, Loder A, Bretzel G, Van Soolingen D, Hale YM, Salfinger M. 2002. Rapid and simple approach for identification of Mycobacterium tuberculosis complex isolates by PCRbased genomic deletion analysis. J Clin Microbiol 40:2339-2345. http://dx .doi.org/10.1128/JCM.40.7.2339-2345.2002.
10. Warren RM, Gey van Pittius NC, Barnard M, Hesseling A, Engelke E, de Kock M, Gutierrez MC, Chege GK, Victor TC, Hoal EG, van Helden PD. 2006. Differentiation of Mycobacterium tuberculosis complex by PCR amplification of genomic regions of difference. Int J Tuberc Lung Dis 10:818-822.
11. Meng M, Smith B, Johnston B, Carter S, Brisson J, Roth SE. 2015. Simultaneous quantitation of delamanid (OPC-67683) and its eight metabolites in human plasma using UHPLC-MS/MS. J Chromatogr B 1002: 78-91. http://dx.doi.org/10.1016/j.jchromb.2015.07.058.
12. Kahlmeter G, Brown DF, Goldstein FW, MacGowan AP, Mouton JW, Odenholt I, Rodloff A, Soussy CJ, Steinbakk M, Soriano F, Stetsiouk O. 2006. European Committee on Antimicrobial Susceptibility Testing (EUCAST) technical notes on antimicrobial susceptibility testing. Clin Microbiol Infect 12:501-503. http://dx.doi.org/10 .1111/j.1469-0691.2006.01454.x.
13. US Department of Health and Human Services/Food and Drug Administration Center for Drug Evaluation and Research. 2009. Guidance for industry: microbiological data for systemic antibacterial drug products: development, analysis, and presentation. HHS/FDA, Rockville, MD.
14. European Medicines Agency. 2013. Assessment report: Deltyba. European Medicines Agency, London, England.
15. Haver HL, Chua A, Ghode P, Lakshminarayana SB, Singhal A, Mathema B, Wintjens R, Bifani P. 2015. Mutations in genes for the F420 biosynthetic pathway and a nitroreductase enzyme are the primary resistance determinants in spontaneous in vitro-selected PA-824-resistant mutants of Mycobacterium tuberculosis. Antimicrob Agents Chemother 59: 5316-5323. http://dx.doi.org/10.1128/AAC.00308-15.
16. Doi N, Disratthakit A. 2006. Characteristic anti-mycobacterial spectra of the novel anti-TB drug candidates OPC-67683 and PA-824, poster F1-1377a. Int Chemother Antimicrob Agents Chemother (ICAAC). American Society for Microbiology, Washington, DC.
17. World Health Organization. 2014. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. Document WHO/HTM/TB/2014.11. World Health Organization, Geneva, Switzerland. http://apps.who.int/iris/bitstream/10665/130918/1 /9789241548809-eng.pdf.
18. World Health Organization. 2014. The use of delamanid in the treatment of multidrug-resistant tuberculosis: interim policy guidance. Document WHO/HTM/TB2014.23. World Health Organization, Geneva, Switzerland.